Zhou Steve R, Choi Moon Hyung, Vesal Sulaiman, Kinnaird Adam, Brisbane Wayne G, Lughezzani Giovanni, Maffei Davide, Fasulo Vittorio, Albers Patrick, Zhang Lichun, Kornberg Zachary, Fan Richard E, Shao Wei, Rusu Mirabela, Sonn Geoffrey A
Department of Urology, Stanford School of Medicine, Palo Alto, CA, USA.
Department of Radiology, Stanford School of Medicine, Palo Alto, CA, USA.
Eur Urol Open Sci. 2024 Jul 13;66:93-100. doi: 10.1016/j.euros.2024.06.017. eCollection 2024 Aug.
Micro-ultrasound (MUS) uses a high-frequency transducer with superior resolution to conventional ultrasound, which may differentiate prostate cancer from normal tissue and thereby allow targeted biopsy. Preliminary evidence has shown comparable sensitivity to magnetic resonance imaging (MRI), but consistency between users has yet to be described. Our objective was to assess agreement of MUS interpretation across multiple readers.
After institutional review board approval, we prospectively collected MUS images for 57 patients referred for prostate biopsy after multiparametric MRI from 2022 to 2023. MUS images were interpreted by six urologists at four institutions with varying experience (range 2-6 yr). Readers were blinded to MRI results and clinical data. The primary outcome was reader agreement on the locations of suspicious lesions, measured in terms of Light's κ and positive percent agreement (PPA). Reader sensitivity for identification of grade group (GG) ≥2 prostate cancer was a secondary outcome.
Analysis revealed a κ value of 0.30 (95% confidence interval [CI] 0.21-0.39). PPA was 33% (95% CI 25-42%). The mean patient-level sensitivity for GG ≥2 cancer was 0.66 ± 0.05 overall and 0.87 ± 0.09 when cases with anterior lesions were excluded. Readers were 12 times more likely to detect higher-grade cancers (GG ≥3), with higher levels of agreement for this subgroup (κ 0.41, PPA 45%). Key limitations include the inability to prospectively biopsy reader-delineated targets and the inability of readers to perform live transducer maneuvers.
Inter-reader agreement on the location of suspicious lesions on MUS is lower than rates previously reported for MRI. MUS sensitivity for cancer in the anterior gland is lacking.
The ability to find cancer on imaging scans can vary between doctors. We found that there was frequent disagreement on the location of prostate cancer when doctors were using a new high-resolution scan method called micro-ultrasound. This suggests that the performance of micro-ultrasound is not yet consistent enough to replace MRI (magnetic resonance imaging) for diagnosis of prostate cancer.
微超声(MUS)使用高频探头,其分辨率优于传统超声,能够区分前列腺癌与正常组织,从而实现靶向活检。初步证据显示,其敏感性与磁共振成像(MRI)相当,但使用者之间的一致性尚待描述。我们的目的是评估多名读者对MUS解读的一致性。
经机构审查委员会批准后,我们前瞻性收集了2022年至2023年因多参数MRI检查后转诊进行前列腺活检的57例患者的MUS图像。MUS图像由四个机构的六名经验各异(2至6年)的泌尿科医生进行解读。读者对MRI结果和临床数据不知情。主要结果是读者对可疑病变位置的一致性,用Light's κ和阳性百分一致性(PPA)衡量。读者识别≥2级前列腺癌的敏感性是次要结果。
分析显示κ值为0.30(95%置信区间[CI] 0.21 - 0.39)。PPA为33%(95% CI 25 - 42%)。总体而言,对于≥2级癌症,患者层面的平均敏感性为0.66 ± 0.05,排除前部病变的病例后为0.87 ± 0.09。读者检测到高级别癌症(≥3级)的可能性高出12倍,该亚组的一致性更高(κ 0.41,PPA 45%)。主要局限性包括无法对读者划定的靶点进行前瞻性活检,以及读者无法进行实时探头操作。
读者对MUS上可疑病变位置的一致性低于先前报道的MRI水平。MUS在前部腺体中检测癌症的敏感性不足。
影像学扫描发现癌症的能力在医生之间可能存在差异。我们发现,当医生使用一种名为微超声的新型高分辨率扫描方法时,对于前列腺癌的位置经常存在分歧。这表明微超声的性能尚未足够一致,无法取代MRI(磁共振成像)用于前列腺癌的诊断。